(TheNewswire)
Vancouver, BC - TheNewswire - May 9, 2023 - A REV Life Sciences GlobalCorp. (CSE:AREV) (OTC:AREVF) (“ AREV ” or the Company ”) AREV Life Sciences is pleased to announce it hascompleted its first phase of AI driven deductive research to identifythe best complimentary natural compounds for use with its proprietaryextracts and Combination Therapy in traditional medicine.
Arev has written and refined an exclusivelibrary of Artificial Intelligence “AI” prompts for the rapidretrieval of data on the most researched and published medicinalcompounds. These prompts were ran through fine tuning iterations andbacktested using Open AI’s GPT 4.0 language platform. The Arevlibrary has been optimized to: 1) Identify the most researched naturaloccurring compounds that have synergistic chemistry with Arev’sproprietary extract s, 2)summarize the published research as it relates to the area of targetedhealth, 3) denote the original source where the compound is found innature 4) denote any known pharmacokinetics and pharmacodynamics and5) list references and citations from the published work the resultscame from, 6) compile a list of the best compounds to use incombination therapy with traditional medicine.
In th e first phase of AIanalysis , the proprietaryprompts instructed the AI agents to act as experts and conduct a deepreview of the top researched (peer reviewed and published) compounds used in pre-clinical and clinical trials andstudies on multiple categories of diseases. The category ofcompounds included b otanical extracts,cannabis sativa L and its individual cannabinoids, lipids, includingOmega 3,6,7,9 , krilloil and MCT oil ,phosphocholine and phosphatidylcholine, polysaccharides, cerebrosides, vitamins andminerals, amino acids, fungi, flavonoids, carotenoids, phytosterols, terpenes andpolyph enols . As a result, we now have a list of the topten researched compounds from each of the chemical categories for using with ourproprietary extracts in conjunction withCombination Therapy with traditional medicine used to treat the diseasesnoted below .
Arev’s proprietary extracts contain a richsource of bioactive molecules that possess diverse pharmacological properties for use as a therapeutic effect for ( but not limited to) the following areasof health; anti-inflammatory, analgesic, h eart disease,cancer (s) ,hepatoprotective agents for Non Alcoholic Fatty Liver Disease, Fibromyalgia, viralinfections and immune deficiencies , anxiety, insomnia, pain-related I nflammation, Alzheimer's (cognitive decline) andwound-healing. Sea cucumber , hops, hemp andginseng extracts forexample, have been researched and validated to possessvarious biological activities that make them suitable for use in combination therapies with other compounds andimprove the efficacy of traditional medicine.
As noted in the British Pharmacological SocietyJournals - Concise Guide to Pharmacology, “ Combination therapies exploit the chances for betterefficacy, decreased toxicity, and reduced development of drugresistance and owing to these advantages, have become a standard forthe treatment of several diseases and continue to represent apromising approach in indications of unmet medical need. In thiscontext, studying the effects of a combination of drugs in order toprovide evidence of a significant superiority compared to the singleagents is of particular interest. ” Source: https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.149
Through phase one we observed theoretical evidence thatArev extracts can benefitfrom combination therapies as noted in the Analysis of DrugCombinations paper published in the Concise Guide to Pharmacology. Theresults of this first phase, generated a body of work thatserves as a resource to bereferred to when lookingto match a researched compound with an Arevextract to a specificsymptom of a disease. The pharmacokinetics have been cross examined aswell to minimize p otential drug interactionsthat may occur when using these compounds with traditionalmedicine. This is a critical piece that supports t he methods and technology A rev has developed. A rev continuesto build on it s core competenc ies of extraction and formulation with advanced technology as it prepares for thecommercialization of its science backed compounds andingredients .
The company now has a valuable library of prompts thatcan be used as is or modified to instruct AI agents to identifycompounds and their pharmacokinetics to determine their efficacy andsynergistic relations to other compounds for application in targetedareas of health when used with Arev extracts for optimal results incombination therapy. These prompts can be applied to further AIdeductive work with extracts combined with other compounds or even toidentify potential drug candidates. Having these tools enable Arev toperform work that would normally take a team of researchers months andin some cases years to complete.
CEO, Michael Withrow stated “Without the deploymentof AI, this type of work, would be too time consuming and just notfeasible for companies like Arev to do what multi billion dollar foodand drug companies do manually in this area as a normal course ofbusiness.” He went on to say, “The use of AI technology on thechemistry of compounds provides Arev (and other who adopt it) with theability to identify combination therapies for use as naturaltherapeutic interventions in clinical nutrition, natural healthproducts, functional foods and beverages. These industries and theirconsumers both stand to benefit greatly with the implementation ofAI.”
The nutritional profile of functional foods and beverages can beimproved and carry structured function claims with the application of this game changing technology. New productscan be manufactured (processed), packaged and sold to consumers.
The company claims copyright ownership of its exclusivelibrary of Artificial Intelligence Instructions “Prompts” andplans to register the library and method internationally. The boardplans to seek council from its Intellectual Property Attorney’s todraft licensing agreements for the use of this method and library ofIP.
For further information, contact Mike Withrow,arevlifesciences@gmail.com 778-929-6536. For more information visitwww.arevlifesciences.com.
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Life Sciences GlobalCorp.
The Company is a fully integrated enterprise withcompetencies in: 1) extraction of compounds for consumption andtopical use. 2) Clinical Nutrition and 3) A technology platform calledMedicine Merchant. The Company produces ingredients and formulatesexclusive therapeutic interventions with plans to deliver innovationin clinical nutrition, proprietary supplements, topicals and rationaldrug design, based on science. The Company’s business modelleverages its core competency of extraction to produce ingredients andcompounds for its pipeline of products. The Company continues in theproduct development and pre-commercialization stage.
AREV is dedicated to designing and deliveringinnovation in rational drug design, driven by presenting globalepidemiological characteristics of multiple challenges tointernational human and animal health. AREV is a member of bothBIOTECanada and The Biotechnology Innovation Organization (BIO).
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITSREGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITYFOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in policies ofthe CSE) accepts responsibility for the adequacy or accuracy of thisrelease. This news release may include forward-looking statements thatare subject to risks and uncertainties. All statements within, otherthan statements of historical fact, are to be considered forwardlooking. Although the Company believes the expectations expressed insuch forward looking statements are based on reasonable assumptions,such statements are not guarantees of future performance and actualresults or developments may differ materially from those inforward-looking statements. Factors that could cause actual results todiffer materially from those in forward-looking statements includemarket prices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as required
under the applicable laws. This press release containsforward-looking statements. The use of any of the words"anticipate", "continue", "estimate","expect", "may", "will","project", "should", "believe" andsimilar expressions are intended to identify forward-lookingstatements. Although the Company believes that the expectations andassumptions on which the forward-looking statements are based arereasonable, undue reliance should not be placed on the forward-lookingstatements because the Company can give no assurance that they willprove to be correct. Since forward-looking statements
address future events and conditions, by their verynature they involve inherent risks and uncertainties. These statementsspeak only as of the date of this press release. Actual results coulddiffer materially from those currently anticipated due to a number offactors and risks various risk factors discussed in the Company’sManagement’s Discussion and Analysis under the Company’s profileon www.sedar.com.
Copyright (c) 2023 TheNewswire - All rights reserved.